An investigation on behalf of investors, who currently hold shares of Imperva, Inc. (NASDAQ: IMPV), was announced concerning whether the takeover of Imperva, Inc. is unfair to NASDAQ: IMPV stockholders.

The investigation by a law firm concerns whether certain officers and directors of Imperva, Inc. (NASDAQ: IMPV breached their fiduciary duties owed to Imperva, Inc. (NASDAQ: IMPV investors in connection with the proposed acquisition.

On Oct. 10, 2018-- Imperva, Inc. (NASDAQ: IMPV) announced it entered into an agreement to be acquired by leading private equity technology investment firm Thoma Bravo, LLC. Under the terms of the agreement, Imperva stockholders will receive $55.75 per share in cash in a transaction valued at approximately $2.1 billion.

However, given that at least one analyst has set the high target price for NASDAQ: IMPV shares at $65.00 per share, the investigation concerns whether the offer is unfair to Imperva, Inc. (NASDAQ: IMPV stockholders. More specifically, the investigation concerns whether the Imperva, Inc. (NASDAQ: IMPV Board of Directors undertook an adequate sales process, adequately shopped the company before entering into the transaction, maximized shareholder value by negotiating the best price, and acted in the shareholders' best interests in connection with the proposed sale.

Imperva, Inc. reported that its annual Total Revenue rose from $264.45 million in 2016 to $321.71 million in 2017 and that its Net Loss of $70.27 million in 20916 turned into a Net Income of $22.86 million in 2017.

Shares of Imperva, Inc. (NASDAQ: IMPV) closed on October 15, 2018, at $55.35 per share.